Castle Biosciences Presents New Data Highlighting Use Of DecisionDx-Melanoma To Identify Early-Stage Melanoma Patients At High Risk Of Metastasis To The Central Nervous System To Prompt Use Of Imaging Surveillance At 2024 ASCO Annual Meeting

Castle Biosciences +5.17%

Castle Biosciences




Castle to present a second poster on its DecisionDx®-UM test sharing data from an ongoing prospective, multi-center study of patients with uveal melanoma (UM) led by the Collaborative Ocular Oncology Group (COOG2)

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will present new data related to its DecisionDx-Melanoma and DecisionDx-UM tests at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 31-June 4, 2024, in Chicago.

Every question you ask will be answered
Scan the QR code to contact us
Also you can contact us via